Compare ESPR & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | BWAY |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 674.2M |
| IPO Year | 2013 | N/A |
| Metric | ESPR | BWAY |
|---|---|---|
| Price | $3.13 | $13.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.75 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 9.9M | 148.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,135,000.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $12.81 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.95 | $10.61 |
| 52 Week High | $4.18 | $26.63 |
| Indicator | ESPR | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 69.52 | 35.13 |
| Support Level | $3.11 | $11.90 |
| Resistance Level | $3.18 | $16.51 |
| Average True Range (ATR) | 0.01 | 0.52 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 75.00 | 2.12 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.